Corcept Therapeutics INC Form 4 insider transactions

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, exercised stock options and subsequently sold shares, partially to cover taxes.

Corcept Therapeutics Director Daniel N. Swisher Jr. exercised options and sold 2,200 common shares for a significant gain under a pre-arranged 10b5-1 plan.

Corcept Therapeutics' Chief Development Officer, William Guyer, sold 35,007 shares of common stock after exercising stock options, pursuant to a pre-arranged 10b5-1 plan.

Corcept Therapeutics Chief Development Officer William Guyer sold 14 shares of common stock after exercising options, as per a pre-arranged 10b5-1 plan.

Corcept Therapeutics President of Endocrinology, Sean Maduck, exercised stock options and sold a significant number of shares, alongside transferring shares to family trusts.

Corcept Therapeutics CEO Joseph K. Belanoff sold 39,000 shares of common stock for approximately $2.7 million through a pre-arranged Rule 10b5-1 trading plan.

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, exercised stock options and sold 5,823 shares of common stock.

Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold a portion of his common stock holdings in Corcept Therapeutics Inc. on July 17 and 18, 2025, under a Rule 10b5-1 trading plan.

Corcept Therapeutics CEO Joseph K. Belanoff sold 615 shares of common stock for approximately $73.69 per share, executed under a pre-existing Rule 10b5-1 trading plan.

Joseph Douglas Lyon, Chief Accounting & Technology Officer at Corcept Therapeutics Inc., executed planned stock option exercises and subsequent share sales.

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold a portion of the acquired common stock on July 17 and 18, 2025, under a pre-arranged 10b5-1 trading plan.

A director at Corcept Therapeutics Inc. exercised stock options and simultaneously sold an equivalent number of common shares, as disclosed in a recent SEC Form 4 filing.

Corcept Therapeutics' Chief Development Officer, William Guyer, sold 100 shares of common stock on July 1, 2025, after exercising stock options, as part of a pre-arranged 10b5-1 plan.

A Corcept Therapeutics officer executed a pre-scheduled transaction, exercising stock options and simultaneously selling an equal number of common shares under a Rule 10b5-1 plan.

Sean Maduck, President of Corcept Endocrinology, exercised stock options and subsequently sold a portion of his common stock holdings in Corcept Therapeutics on July 1, 2025, as part of a pre-arranged 10b5-1 trading plan.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc., sold 3,185 shares of common stock at $70.77 per share on June 16, 2025, as part of a pre-arranged trading plan.

Corcept Therapeutics Inc. Director Gillian Cannon was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.

Corcept Therapeutics Inc. director Joshua M. Murray was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.

Corcept Therapeutics Inc. director James N. Wilson was granted 25,000 stock options with an exercise price of $72.27, vesting monthly over one year.

Corcept Therapeutics Inc. director Kimberly Park was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.

A director at Corcept Therapeutics exercised stock options and sold an equivalent number of shares, while also receiving a new grant of stock options.

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold 20,000 shares of common stock for approximately $1.45 million, reducing his direct beneficial ownership.

Corcept Therapeutics Inc. Director Gregg H. Alton was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.

Corcept Therapeutics Inc. director David L. Mahoney was granted 15,000 stock options with an exercise price of $72.27, vesting monthly over one year.

G. Leonard Baker Jr., a Director and 10% Owner of Corcept Therapeutics Inc., was granted 15,000 stock options exercisable at $72.27 per share.

Joseph K. Belanoff, CEO and Director of Corcept Therapeutics Inc., sold 39,000 shares of common stock on June 2, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics Inc., reported a series of equity transactions including option exercises, stock sales under a 10b5-1 plan, and new restricted stock awards.

Corcept Therapeutics' President of Endocrinology, Sean Maduck, executed a series of transactions including the exercise of stock options, acquisition of shares through a purchase plan and restricted stock awards, and the sale of common stock, all under a pre-arranged 10b5-1 trading plan.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc., has increased his beneficial ownership in the company through a share purchase plan and the grant of restricted stock awards.

Corcept Therapeutics' Chief Financial Officer, Atabak Mokari, reported the acquisition of 1,550 shares through a purchase plan and restricted stock awards, alongside the disposition of 519 shares for tax withholding purposes, increasing his total beneficial ownership to 14,065 shares.